Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L34 pseudogene 18 (RPL34P18) is classified as a pseudogene, meaning it shares sequence similarity with the functional ribosomal protein L34 gene but is not transcribed into a functional protein[2][1][8]. Pseudogenes like RPL34P18 arise through duplication or retrotransposition events during evolution and generally do not produce active proteins or carry out the biological roles of their parent genes[5][2]. RPL34P18 is thus not considered a therapeutic target, receptor, enzyme, nor is it implicated in drug interaction or disease biomarker development. There are no functional or pharmacological data, and its designation as a target is incorrect due to its non-coding status[2][1][8].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 18 (RPL34P18).